T 1063/18 (Extreme dark green, blocky peppers/SYNGENTA) 05-12-2018

Reasons for the Decision

1. The appeal complies with Articles 106 to 108 and Rule 99 EPC and is therefore admissible.

Main request

Exception to patentability under Article 53(b) EPC in conjunction with Rule 28(2) EPC

2. Exception to patentability under Article 53(b) EPC in conjunction with Rule 28(2) EPC of the subject-matter of claims 1 and 2 was the sole reason given in the decision under appeal for refusing the application.

3. Article 53(b) EPC excludes from patentability "plant or animal varieties or essentially biological processes for the production of plants or animals".

Decisions G 2/12 and G 2/13

4. Decisions G 2/12 (OJ EPO 2016, A27; Tomato II) and G 2/13 (OJ EPO 2016, A28; Broccoli II) of the Enlarged Board of Appeal (EBA) concern the patentability of plants directly obtained by and/or defined by an essentially biological process, the meaning of "essentially biological process for the production of plants" having already been defined in decisions G 2/07 (OJ EPO 2012, 130; Broccoli I) and G 1/08 (OJ EPO 2012, 206; Tomato I). The EBA considered that what remained to be determined was: whether or not the exclusion from patentability of essentially biological process for the production of plants "is limited to method or process claims or whether it also encompasses a patent claim for a product that is directly obtained and/or defined by an 'essentially biological process'." The EBA gave an interpretation of the meaning of this aspect of Article 53(b) EPC, considering its wording, the legislator's intention and taking into account the aspect of subsequent agreement and practice within the meaning of Article 31(3) Vienna Convention on the law of treaties, concluded at Vienna on 23 May 1969 (further referred to as: the Vienna Convention), as well as a systematic and historical interpretation (see Reasons, point VII.).

5. The EBA stated that applying the various methodical lines of interpretation to Article 53(b) EPC pointed towards not extending the scope of the process exclusion pursuant to Article 53(b) EPC "directly to a product claim or a product-by-process claim directed to plants or plant material such as a fruit, or to plant parts other than a plant variety" (see Reasons, points VII.6.(2) and (3)).

6. As secondary considerations, for "testing the legal soundness of the conclusions reached in interpreting the scope of application of the process exclusion under Article 53(b) EPC" in accordance with traditional means of interpretation, the EBA considered the questions

(i) whether there was a need for a dynamic interpretation of Article 53(b) EPC, due to factors that had arisen since the Convention was signed and which could have given grounds for assuming that a restrictive reading of the wording of Article 53(b) EPC, when applying the general principles of interpretation, conflicted with the legislator's intention and (ii) whether allowing the patentability of a product claim directed to a fruit and of a product-by process claim directed to a plant or plant material rendered the exception to patentability of essentially biological processes for the production of plants meaningless ("legal erosion") (see Reasons, points VIII.(1).(a) and (b)).

7. In the context of considering whether a dynamic interpretation of Article 53(b) EPC was warranted, the EBA noted that the fact that "subsequent developments in the field of plant breeding techniques did not prompt the legislator to revise the process exclusion such that it was extended to plant products obtained by essentially biological processes" and came to the conclusion that the concept of a dynamic interpretation did not require revising the result of the interpretation established by applying traditional rules of construction (see Reasons, point VIII.1.)

8. In the context of considering a possible "legal erosion", the EBA pointed out that it was aware of the various ethical, social and economic aspects in the debate with regard to the questions posed to it and also that it had noted that in some Contracting States, namely Germany and the Netherlands, national legislation was amended to exclude product claims from patentability where the claimed products had been generated by an essentially biological process for the production of plants, while in other Contracting States no such amendments have been made. The EBA underlined that its role, however, was to interpret the EPC using general accepted principles of interpretation of international treaties and that it was not mandated to engage in legislative policy (see Reasons, point VIII.2.(c)).

9. As a result of its secondary considerations, the EBA saw neither a need nor a legal justification for altering the understanding of Article 53(b) EPC achieved by applying the traditional means of interpretation (see Reasons, point VIII.3).

10. Thus, in decisions G 2/12 and G 2/13, the EBA concluded that the scope of application of the term "essentially biological processes for the production of plants" in Article 53(b) EPC is interpreted to the effect that product inventions where the claimed subject-matter is directed to plants or plant material such as a fruit or plant parts other than a plant variety, as such, are not excluded from being patented (see Reasons, point IX.(1)).

The Notice

11. The Notice states that, after the decisions of the EBA in the Tomato II and Broccoli II cases, the European Parliament asked the European Commission to look, inter alia, into the patentability of products derived from essentially biological processes. It is stated in the introductory part that: "(...) this Notice sets out the Commission's views on the patentability of products emanating from essentially biological processes (addressed in Article 4 of the Directive). (...) The Notice is intended to assist in the application of the Directive, and does not prejudge any future position of the Commission on the matter. Only the Court of Justice of the European Union is competent to interpret Union law" (Introduction, penultimate paragraph).

12. It is furthermore stated under the heading

1. Exclusion from patentability of products obtained by essentially biological processes "While these decisions of March 2015 [G 2/12 and G 2/13 of the EBA] are in line with the intentions of the drafters of the EPC, it is questionable whether the same result would have been reached in the EU context" and furthermore that "When trying to assess the intentions of the EU legislator when adopting the Directive, the relevant preparatory work to be taken into consideration is not the work which preceded the signature of the EPC in 1973, but that which relates to the adoption of the Directive."

13. The Notice therefore discusses aspects of the preparatory work leading to the Biotech Directive, starting with the European Commission proposal of December 1995 and mentions subsequent amendments and deletions by the European Parliament. It emphasises that the specific reference to the non-patentability of plants and animals obtained by an essentially biological process was removed from the text only because it was explicitly stated that biological material which was isolated from its natural environment, or processed by means of a technical process could be the subject of an invention. The removal of the specific reference did not mean however, that the parliament intended to eliminate the exclusion of plants or animals obtained by essentially biological processes from patentability. As evidence for this, reference is made to the explanatory statement accompanying the "Report of the Committee on Legal Affairs and Citizens' Rights of the European Parliament on the proposal for a European Parliament and Council Directive on the legal protection of biotechnological inventions of 25 June 1997" ("Rothley report"), in particular to the following passage:

"'Essentially biological procedures', i.e. crossing and selection of the whole genome [...] do not meet the general conditions for patentability, as they are neither inventive nor reproducible. Breeding is a reiterative process, in which a genetically stable end- product with the required characteristics is attained only after much crossing and selection. This process is so strongly marked by the individuality of the initial and intermediate material that an identical result will not be obtained upon its repetition. Patent protection is not appropriate for such procedures and their products".

14. The Notice puts forward that "having regard to the preparatory work related to the Directive [...], certain provisions of the Directive are only consistent if plants/animals obtained from essentially biological processes are understood as being excluded from its scope" and then goes on to analyse the interdependency of several articles and of recital 32 of the Biotech Directive.

15. The Notice concludes that "The Commission takes the view that the EU legislator's intention when adopting Directive 98/44/EC, was to exclude from patentability products (plants/animals and plant/animal parts) that are obtained by means of essentially biological processes."

Proposed amendment of the Implementing Regulations

16. In document CA/56/17, addressed to the Administrative Council of the European Patent Organisation, the President of the European Patent Office proposed that the Implementing Regulations to the EPC be amended to the effect that - in accordance with the interpretation of the Biotech Directive developed in the Notice - plants and animals produced by essentially biological processes be excluded from patentability.

Rule 28(2) EPC

17. In a decision of the Administrative Council of 29 June 2017 (CA/D 6/17), taken on the basis of

Article 33(1)(c) EPC, a new paragraph 2 was added to Rule 28 of the Implementing Regulations to the EPC reading:

"(2) Under Article 53(b), European patents shall not be granted in respect of plants or animals exclusively obtained by means of an essentially biological

process."

Is Rule 28(2) EPC in conflict with Article 53(b) EPC?

18. The board has the following considerations regarding the appellant's line of argument as set out in

section IX(a) above, that Rule 28(2) EPC is in conflict with Article 53(b) EPC as interpreted by the EBA.

19. Under Article 22(1)(a) EPC, the EBA is the judicial body entrusted with deciding and giving opinions on points of law referred to it under Article 112(1)(a) and (b) EPC in order to ensure uniform application of the law. The EBA issued decisions G 2/12 and G 2/13 providing answers to the question of the interpretation of Article 53(b) EPC in relation to the issue of whether a plant that is directly obtained by and/or defined by an essentially biological process is excluded from patentability by Article 53(b) EPC (see point 10, above).

20. It is noted that, in view of Article 112(3) EPC, the binding effect of decisions of the EBA on a board under Article 112(1)(a) EPC, applies only to the board of appeal in respect of the appeal which gave rise to the referral. However, these decisions have a de facto binding effect on the Boards of Appeal, up to the point at which they consider it necessary to deviate from them, at which point they must refer the question to the EBA. This follows from Article 21 RPBA which stipulates that: "Should a Board consider it necessary to deviate from an interpretation or explanation of the Convention contained in an earlier opinion or decision of the Enlarged Board of Appeal, the question shall be referred to the Enlarged Board of Appeal".

21. Moreover, any interpretation of the EPC by the EBA implies that the law should always have been read in conformity with that interpretation (see decisions G 9/93, OJ EPO 1994, 891, Reasons, point 6.1; G 3/97, OJ EPO 1999, 245, Reasons, point 7). An interpretation of the EPC by the EBA is thus to be applied to all cases pending before the departments of the European Patent Office and before the Boards of Appeal and in all subsequent cases, unless the EBA provides transitional provisions.

22. By decision of the Administrative Council of 29 June 2017, Rule 28(2) EPC was introduced into the Implementing Regulations (see point 17, above) with a view of aligning them with the interpretation of the Biotech Directive set forth in the Notice by clarifying that "plants and animals as well as propagation materials thereof are covered by the exclusion from patentability" (CA/56/17, points 59 and 64).

23. In the decision under appeal, the examining division reasoned that Rule 28(2) EPC constitutes a "clarification of the scope of Article 53(b) EPC". The board however cannot deduce from decisions G 2/12 and G 2/13 any other interpretation of Article 53(b) EPC than that plants are not excluded from patentability, even if they can only be obtained by an essentially biological process. Since Rule 28(2) EPC excludes plants or animals exclusively obtained by means of an essentially biological process from patentability, its meaning is in conflict with the meaning of Article 53(b) EPC as interpreted by the EBA.

Can the conflict be resolved by way of interpretation?

24. The case law of the EBA and the Boards of Appeal shows that in some cases, potential contradiction between a Rule of the Implementing Regulations and the provisions of the EPC can be avoided by interpreting the potentially conflicting Rule in such a way that no contradiction exists (see e.g. decisions G 2/95,

OJ EPO 1996, 555, Reasons, points 1 and 2; G 6/95,

OJ EPO 1996, 649, Reasons, point 5). However, in the present case, Rule 28(2) EPC in fact reverses the meaning of Article 53(b) EPC, as interpreted by the EBA. In view of this direct contradiction, interpreting Rule 28(2) EPC in such a way that no contradiction exists is not possible.

25. The board therefore concurs with the appellant's view, as set out in section IX(a) above, that Rule 28(2) EPC is in conflict with Article 53(b) EPC as interpreted by the EBA.

Are there reasons to deviate from G 2/12 and G 2/13?

26. The board recognises "the Administrative Council's power to lay down provisions concerning substantive law in the Implementing Regulations" as recognised in decision G 2/07 (see Reasons, point 2.2). However, in point 2.2 of this decision it is also noted that "The limits to the Administrative Council's law-making powers by means of the Implementing Regulations can be inferred from Article 164(2) EPC". According to that Article, in case of conflict between the provisions of the Convention and those of the Implementing Regulations, the provisions of the Convention shall prevail. Thus the board agrees with the finding in decision T 39/93 (see Reasons, point 3.2) that "the meaning of an Article of the EPC (...), on its true interpretation as established by a ruling of the Enlarged Board of Appeal cannot, (...), be overturned by a newly drafted Rule of the Implementing Regulations, the effect of which is to conflict with this interpretation". The board concludes that it must apply decisions G 2/12 and G 2/13 unless it has reasons to refer the same question underlying these decisions for reconsideration by the EBA.

27. Where a question of law has been answered in a decision of the EBA, according to Article 21 RPBA a referral on the same point of law is required if the board considers it necessary to deviate from the interpretation of the Convention contained in the decision of the EBA.

28. Therefore, the board considered whether there were reasons to deviate from the interpretation of Article 53(b) EPC given by decisions G 2/12 and G 2/13 due to developments occurring after said decisions were issued.

29. The interpretation of the Biotech Directive as put forward in the Notice cannot be seen as a relevant development because it has not been confirmed in a legally binding way. Within the legal framework of the European Union (EU), a binding interpretation of provisions of EU law such as the Biotech Directive are decided in last instance by the CJEU (Article 267(b) Treaty on the Functioning of the European Union). This was recognised in the Notice itself (see point 11, above). The Notice therefore has no legal authority.

30. In decisions G 2/12 and G 2/13, the EBA considered whether a Rule of the Implementing Regulations could be regarded as a subsequent agreement or practice between the parties on the interpretation of the treaty or its application under Article 31(3) of the Vienna Convention. This question was left unanswered (see Reasons, point VII.4.(1) and (2)).

31. In view of this consideration of the EBA, the board addressed the question of whether an interpretation of Article 53(b) EPC, different from that given in decisions G 2/12 and G 2/13, is necessary in view of Article 31(3)(a) of the Vienna Convention in particular. This provision stipulates that, for the purpose of interpreting a treaty "there shall be taken into account, together with the context: (a) Any subsequent agreement between the parties regarding the interpretation of the treaty or the application of its provisions".

32. If the adoption of Rule 28(2) EPC by the Administrative Council (see CA/D 6/17 and point 17 above) were to be considered a subsequent agreement in the sense of the Vienna Convention and used for the interpretation of Article 53(b) EPC, this would reverse the meaning of Article 53(b) EPC as interpreted by the EBA (see point 24 above), i.e. it would represent an amendment of an Article of the Convention.

33. The Administrative Council is competent to amend an Article of the Convention pursuant to Articles 33(1)(b) and 35(3) EPC. The Administrative Council is therefore competent to amend "Parts II to VIII and Part X of this Convention, to bring them into line with an international treaty relating to patents or European Community legislation relating to patents".

34. However, the Administrative Council is not, in the light of Articles 33(1)(b)and 35(3) EPC, competent to amend the Convention, here Article 53(b) EPC, by amendment of the Implementing Regulations, here Rule 28(2) EPC.

35. Although the Administrative Council is also competent to amend the Implementing Regulations pursuant to Article 33(1)(c) EPC, this competence does not extend to amending an Article of the Convention, here Article 53(b) EPC (see point 26 above).

36. Consequently, the decision to adopt Rule 28(2) EPC cannot be regarded as a subsequent agreement between the parties that shall be taken into account for the interpretation of the treaty, in the meaning of Article 31(3)(a) of the Vienna Convention.

37. It goes without saying, that the Notice is not such a subsequent agreement either, as the Commission does not represent the Contracting States of the EPC.

38. In view of the above, the board considers that it is not necessary to deviate from the interpretation of Article 53(b) EPC given by the EBA in decisions G 2/12 and G 2/13.

39. The EBA has given an interpretation of Article 53(b) EPC from which the board sees no reason to deviate. Furthermore, no point of law arises in relation to the course of action in case of a conflict between a Rule of the Implementing Regulations and an Article of the Convention because this situation is governed by Article 164(2) EPC. For these reasons a referral under Article 112(1)(a) EPC is not justified.

The third party's arguments that go against the view of the appellant

40. The board considered the arguments brought forward by third parties, especially the arguments of the third party whose views contradict the view of the appellant (see section XI, above).

41. With respect to the argument concerning the interest of plant breeders to freely perform crossing and selection without being hampered by patents, the board is also aware of the interest of inventors to benefit from their work and that of society to encourage technical development. However, balancing these interests is a matter for the legislative body. Such considerations cannot play a role in the legal assessment of the issues raised in the present case.

42. As the board is persuaded by the appellant's first line of argument, set out in section IX(a) above, the issue of whether or not the Notice adopted a narrow interpretation of essentially biological processes or referred to an alleged broader interpretation of essentially biological processes as defined in decisions G 2/07 and G 1/08 (see section IX(b), above) need not be considered.

43. The view that Rule 28(2) EPC served to ensure consistency between the Biotech Directive and the EPC and with that legal certainty, is based on the presumption that the Biotech Directive has to be interpreted as set out in the Notice. As explained under point 29 above, such a presumption is not valid unless the CJEU has decided on the matter, which it has not. In fact, adopting the interpretation of the Notice in the absence of a decision of the CJEU on the matter, creates a risk of misaligning the provisions of the EPC with the Biotech Directive, should the CJEU later concur with the analysis of the EBA.

44. It is reasonable to presume that the EBA would have taken the Notice into consideration if it had existed at the time of adoption of decisions G 2/12 and G 2/13. However, in the light of the conclusions the EBA drew from the different lines of interpretation, there is no reason to assume that it would have found the Notice decisive for its findings.

45. Thus, the arguments of the third party are not persuasive.

Conclusion with regard to Rule 28(2) EPC

46. Having established that Rule 28(2) EPC is in conflict with Article 53(b) EPC as interpreted by the EBA and in view of Article 164(2) EPC, it must be concluded that the provisions of the Convention prevail.

47. Thus, the decision under appeal, holding the subject-matter of claims 1 and 2 to be within the exception to patentability of Article 53(b) EPC and Rule 28(2) EPC, is to be set aside. The appeal is found to be allowable.

Remittal (Article 111(1) EPC)

48. Pursuant to Article 111(1) EPC, following the examination as to the allowability of the appeal, the board will decide on the appeal and, in this respect, it may either exercise any power within the competence of the department which was responsible for the decision or remit the case to that department for further prosecution.

49. The board was of the preliminary opinion that the claims of the main request had deficiencies under Articles 84 and 56 EPC (see section IV, above).

50. During the oral proceedings before the board, the appellant offered to submit evidence to the effect that the San Luis Ancho plant disclosed in document D1 differed from the claimed plant not only in the shape of its fruit but also in its physicochemical properties.

51. Having regard to the fact that the provision of experimental evidence takes a certain time and to the appellant's request for a remittal of the case, the board decides to remit the case to the examining division for further prosecution, thereby giving the appellant the possibility both to submit further evidence and to have its case heard by two instances.

52. Since appellant's main request is allowed, there is no need to consider their auxiliary requests.